Skip to main content

Advertisement

Log in

Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are a combined treatment modality considered for selected patients with peritoneal carcinomatosis from colorectal and appendiceal cancer. Mitomycin C is a drug often used in this clinical setting. The surgical and clinical factors that may influence the pharmacokinetics of hyperthermic intraperitoneal chemotherapy should be further elucidated.

Materials and methods

The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen. The effect of clinical and surgical factors on drug distribution after single intraperitoneal bolus administration with mitomycin C was determined.

Results

The pharmacokinetics of 145 patients treated with intraperitoneal mitomycin C showed a 27 times greater exposure to peritoneal surfaces when compared to plasma. At 90 min, 29% of the drug remained in the chemotherapy solution, 62% was retained in the body, and 9% was excreted in the urine. The extent of peritonectomy increased the clearance of mitomycin C from the peritoneal space (p = 0.051). A major resection of visceral peritoneal surface and a contracted peritoneal space reduced drug clearance. A contracted peritoneal space significantly reduced (p = 0.0001) drug concentrations in the plasma.

Conclusions

Surgical and clinical factors may require modifications of drug dose or timing of chemotherapy administration. A large visceral resection and a contracted peritoneal space caused a reduced mitomycin C clearance. Total diffusion surface is an important determinant of mitomycin C pharmacokinetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Verwaal VJ, Bruin S, Boot H, Van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–2432

    Article  PubMed  Google Scholar 

  2. Sugarbaker PH (2009) Epithelial appendiceal neoplasms. Cancer J 15:225–235

    Article  PubMed  Google Scholar 

  3. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC (1981) Enhancement by hyperthermia of the in vitro cytotoxicity of Mitomycin C toward hypoxic tumor cells. Cancer Res 41:1096–1099

    PubMed  CAS  Google Scholar 

  4. Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermo chemotherapy given at mild temperatures. Int J Hyperthermia 15:79–107

    Article  PubMed  CAS  Google Scholar 

  5. Link KH, Leder G, Pillasch J, Butzer U, Staib L, Kornmann M, Bruckner U, Beger HG (1998) In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol 14:189–201

    Article  PubMed  CAS  Google Scholar 

  6. Fujita T, Tamura T, Yamada H, Yamamoto A, Muranishi S (1997) Pharmacokinetics of mytomycin C(MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. J Drug Target 4:289–296

    Article  PubMed  CAS  Google Scholar 

  7. Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40:1165–1168

    PubMed  CAS  Google Scholar 

  8. Gilly FN, Carry PY, Sayag AC, Panteix G, Manchon M, Rochette A, Peix JL, Baulieux J, James I, Braillon G (1992) Tolerance of intraperitoneal chemohyperthermia with mitomycin C: in vivo study in dogs. Int J Hyperthermia 8:659–666

    Article  PubMed  CAS  Google Scholar 

  9. Murphy EM, Sexton R, Moran BJ (2007) Early results of surgery in 123 patients with pseudomyxoma peritonei from perforated appendiceal neoplasm. Dis Colon Rectum 50:37–42

    Article  PubMed  Google Scholar 

  10. Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20:61–69

    Article  PubMed  Google Scholar 

  11. Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y, Msika S (2008) Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol 34:1246–1252

    PubMed  CAS  Google Scholar 

  12. Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M (2009) Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 16:463–472

    Article  PubMed  CAS  Google Scholar 

  13. Sugarbaker PH (1999) Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 43(Suppl):S15–S25

    Article  PubMed  Google Scholar 

  14. Esquivel J (2009) Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea. Cancer J 15:249–254

    Article  PubMed  Google Scholar 

  15. Van Ruth S, Verwaal VJ, Zoetmulder FAN (2003) Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 12:771–780

    Article  PubMed  Google Scholar 

  16. Elias DM, Sideris L (2003) Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 12:755–769

    Article  PubMed  Google Scholar 

  17. Sugarbaker PH, Stuart OA, Carmignani CP (2006) Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 57:703–708

    Article  PubMed  CAS  Google Scholar 

  18. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42

    Article  PubMed  CAS  Google Scholar 

  19. De Lima Vazquez V, Sugarbaker PH (2003) Total anterior parietal peritonectomy. J Surg Oncol 83:261–263

    Article  Google Scholar 

  20. De Lima Vazquez V, Sugarbaker PH (2003) Cholecystectomy, lesser omentectomy and stripping of the omental bursa, a peritonectomy procedure. J Surg Oncol 84:45–49

    Article  Google Scholar 

  21. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267–272

    Article  PubMed  CAS  Google Scholar 

  22. Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58

    Google Scholar 

  23. Dalton JT, Geuns ER, Au JL (1989) High performance liquid chromatography determination of mitomycin C in rat and human plasma and urine. J Chromatogr Biomed Appl 495:330–337

    Article  CAS  Google Scholar 

  24. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH (1998) Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies. Oncology 55:130–138

    Article  PubMed  CAS  Google Scholar 

  25. Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL (1991) Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51:4347–4354

    PubMed  CAS  Google Scholar 

  26. Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, Garbit F, Grandclément E, Vignal J, Gilly FN (2000) Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88:2512–2519

    Article  PubMed  CAS  Google Scholar 

  27. Loggie BW, Fleming RA (1996) Complications of heated intraperitoneal chemotherapy and strategies for prevention. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwer Academic Publishers, Boston, pp 221–233

  28. Fernandez-Trigo V, Stuart OA, Stephens AD, Hoover LD, Sugarbaker PH (1996) Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. Cancer Treat Res 81:51–61

    PubMed  CAS  Google Scholar 

  29. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1998) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237

    Article  Google Scholar 

  30. Fujimoto S, Shrestha RD, Kokobun M, Kobayashi K, Kiuchi S, Konno C, Koike S, Okui K (1989) Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg Cancer Treat 2:198–202

    Google Scholar 

  31. Panteix G, Guillaumont M, Cherpin L, Cuichard J, Gilly FN, Carry PY, Sayag A, Salle B, Brachet A, Bienvenu J (1993) Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology 50:366–370

    Article  PubMed  CAS  Google Scholar 

  32. Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, Bartlett DL (2001) Laparoscopic continuous hyperthermic peritoneal perfusion. J Am Coll Surg 193:225–229

    Article  PubMed  CAS  Google Scholar 

  33. De Lima Vazquez V, Stuart OA, Sugarbaker PH (2003) Extent of a parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol 52:108–112

    Article  PubMed  Google Scholar 

  34. Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M (2004) Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15:1558–1565

    Article  PubMed  CAS  Google Scholar 

  35. Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3 Suppl 4):1–6

    PubMed  CAS  Google Scholar 

  36. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG (1985) A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol 248:F425–F435

    PubMed  CAS  Google Scholar 

  37. Flessner MF (2005) The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 288:433–442

    Article  Google Scholar 

  38. Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D (2008) Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol 15:339–344

    Article  PubMed  Google Scholar 

  39. Thomas F, Ferron G, Gesson-Paute A, Hristova M, Lochon I, Chatelut E (2008) Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 15:3623–3624

    Article  PubMed  Google Scholar 

  40. Khatri VP (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a panacea or just an obstacle course for the patient? J Clin Oncol 28:5–7

    Article  PubMed  Google Scholar 

  41. Bachur NR, Gordon SL, Gee MV, Kon H (1979) NADPH cytochrome P-450 reductase activation of quinine anticancer agents to free radicals. Proc Natl Acad Sci USA 2:954–957

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul H. Sugarbaker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van der Speeten, K., Stuart, O.A., Chang, D. et al. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 68, 147–156 (2011). https://doi.org/10.1007/s00280-010-1460-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1460-4

Keywords

Navigation